Biotech · Public company · Millbrae, CA, US
Eikon Therapeutics, Inc.
Ticker EIKN · SEC CIK 0001861123
Track this companyFree. Adds Eikon Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials106 recruiting or active
Pipeline programs21From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline21
- EIK1001Phase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- EIK1001Phase 3 · Non Small Cell Lung Cancer (Squamous or Non Squamous)ClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxel + CarboplatinPhase 3 · Non Small Cell Lung Cancer (Squamous or Non Squamous)ClinicalTrials.gov · fetched Nov 12, 2026
- Paclitaxel + CarboplatinPhase 3 · Non Small Cell Lung Cancer (Squamous or Non Squamous)ClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA® )Phase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®)Phase 3 · Non Small Cell Lung Cancer (Squamous or Non Squamous)ClinicalTrials.gov · fetched Nov 12, 2026
- Pemetrexed + Cisplatin /CarboplatinPhase 3 · Non Small Cell Lung Cancer (Squamous or Non Squamous)ClinicalTrials.gov · fetched Nov 12, 2026
- BDB001Phase 2 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- EIK1001Phase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- EIK1004-001 (IMP1707-001)Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- EIK1005Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IMP1734Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab (KEYTRUDA® )Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- BDB001 (EIK1001)Phase 1 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- BDB018Phase 1 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.PHASE2_PHASE3 · RECRUITING · started Jun 15, 2026ClinicalTrials.gov NCT07365319 · fetched Nov 12, 2026
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsPHASE1_PHASE2 · RECRUITING · started Jan 20, 2026ClinicalTrials.gov NCT07262619 · fetched Nov 12, 2026
- Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.PHASE2_PHASE3 · RECRUITING · started May 22, 2025ClinicalTrials.gov NCT06697301 · fetched Nov 12, 2026
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.PHASE1_PHASE2 · RECRUITING · started Apr 30, 2025ClinicalTrials.gov NCT06907043 · fetched Nov 12, 2026
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 6, 2024ClinicalTrials.gov NCT06246110 · fetched Nov 12, 2026
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Dec 11, 2023ClinicalTrials.gov NCT06253130 · fetched Nov 12, 2026
- BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsPHASE2 · COMPLETED · started Aug 30, 2021ClinicalTrials.gov NCT04819373 · fetched Nov 12, 2026
- Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsPHASE1 · COMPLETED · started Jun 22, 2021ClinicalTrials.gov NCT04840394 · fetched Nov 12, 2026
- BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabPHASE1 · COMPLETED · started Nov 21, 2019ClinicalTrials.gov NCT04196530 · fetched Nov 12, 2026
- BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabPHASE1 · COMPLETED · started Feb 15, 2018ClinicalTrials.gov NCT03486301 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Oct 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026